Profil
Wen Luo is the founder of Denovo Biopharma Co., Ltd.
He currently holds the position of Chairman & Chief Executive Officer at the company, which was founded in 2012.
Postes actifs de Wen Luo
| Sociétés | Poste | Début |
|---|---|---|
Denovo Biopharma Co., Ltd.
 Denovo Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Denovo Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Beijing, China. Denovo Biopharma uses novel biomarker approaches to execute efficient clinical trials in targeted patient populations to optimize the probability of successful trials. The Chinese company has eight late clinical stage drugs in its pipeline addressing major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with rights. Denovo Biopharma seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. The company designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma is enrolling patients in a phase 3 clinical trial for its lead asset db102 (enzastaurin) in diffuse large B-cell lymphoma (DLBCL) and will start a phase 2b study in glioblastoma (GBM). The company has four additional late-stage programs targeting major unmet needs\: db103 for schizophrenia, db104 for depression, db105 for Alzheimer's disease, and db106 for acute myeloid leukemia (AML). Denovo Biopharma is a next-generation biomarker partner to personalize your drug. The company was founded in 2012 by Wen Luo. | Directeur Général | 21/02/2012 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Denovo Biopharma Co., Ltd.
Denovo Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Denovo Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Beijing, China. Denovo Biopharma uses novel biomarker approaches to execute efficient clinical trials in targeted patient populations to optimize the probability of successful trials. The Chinese company has eight late clinical stage drugs in its pipeline addressing major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with rights. Denovo Biopharma seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. The company designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma is enrolling patients in a phase 3 clinical trial for its lead asset db102 (enzastaurin) in diffuse large B-cell lymphoma (DLBCL) and will start a phase 2b study in glioblastoma (GBM). The company has four additional late-stage programs targeting major unmet needs\: db103 for schizophrenia, db104 for depression, db105 for Alzheimer's disease, and db106 for acute myeloid leukemia (AML). Denovo Biopharma is a next-generation biomarker partner to personalize your drug. The company was founded in 2012 by Wen Luo. | Health Technology |
